Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

NCT01478685 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01478685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01478685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2011
Completion date
November 17, 2015
Enrollment
169 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, pancreatic ductal, carcinoma, transitional cell, fallopian tube neoplasms, ovarian neoplasms, peritoneal neoplasms, tumor virus infections, urinary bladder neoplasms